PTP peptide
PTP peptide is a specific Plectin-1 binder. PTP peptide can serve as a component of imaging agents; when conjugated with magnetofluorescent nanoparticles, it enables the detection of small pancreatic ductal adenocarcinomas and precancerous lesions via in vivo confocal microscopy and MRI. When conjugated with imaging agents, PTP peptide specifically targets pancreatic ductal adenocarcinoma cells, and can be used for tumor visualization and compound delivery. PTP peptide is applicable to research related to pancreatic ductal adenocarcinoma.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 1192023-11-2
- Formule: C36H64N8O10
- Masse moléculaire:768.94
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform Radionuclide-Drug Conjugates (RDCs)
More
Activité biologique
|
RDC Peptide |
The PTP peptide (1 h) displayed on phage clone 27 exhibits strong and specific binding to pancreatic ductal adenocarcinoma (PDAC) cells (MNA, 8988, SW1990, MIA-PaCa-2, ASPC), while its binding to normal ductal cells is extremely weak[2].
After being displayed on phage clone 27, the PTP peptide (1 h) specifically binds to in vitro mouse PanIN lesion tissues and mouse PDAC lesion tissues, but does not bind to normal pancreatic tissues[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
[68Ga]Ga-NOTA-PTP (intravenous injection; single dose) specifically accumulates in netrin-1-expressing KPC pancreatic ductal adenocarcinoma xenografts, with a peak uptake of 2.69 %ID/g at 0.5 h post-injection, and exhibits a favorable tumor-to-background ratio by 1.5 h[1].
[68Ga]Ga-NOTA-PTP (intravenous injection; single dose; 0.925-9.6 MBq) shows extremely low uptake in MIN-6 pancreatic ductal adenocarcinoma xenografts with low netrin-1 expression, reaching 0.69 %ID/g at 0.5 h post-injection[1].
[68Ga]Ga-NOTA-PTP (7.4-9.6 MBq; intravenous injection; single dose) enables clear visualization of orthotopic pancreatic ductal adenocarcinoma and peritoneal metastases in KPC mice at 45 min post-injection, and exhibits superior tumor-to-background contrast compared with 2-[18F]FDG[1].
[68Ga]Ga-NOTA-PTP (7.4-9.6 MBq; intravenous injection; single dose) accumulates in plectin-1-expressing 4T1 breast cancer xenografts, with distinct uptake detectable at 30 min post-injection[1].
After conjugation of PTP peptide (administered via tail vein injection) with ICG to form ICG-PTP, the conjugate is administered to mice. At 24 h, it reaches a T/N ratio of 6.74 in subcutaneous PDAC tumors, enabling precise fluorescence-guided surgical resection with no postoperative tumor recurrence, and effectively mediating photothermal ablation to increase the tumor temperature by 13.0 °C[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude (female, 18−20 g, subcutaneous xenograft via injection of 5×10^6 CFPAC-1 cells)[1]
-
Dosage:7.4−9.6 MBq ([68Ga]Ga-NOTA-PTP); 0.46 μmol (unlabeled NOTA-PTP)
-
Administration:i.v.; single dose; i.v.; single coadministered dose
-
Result:Visualized tumors distinctly as early as 0.5 h postinjection, with tracer uptake measured at 1.65 %ID/g, decreasing to 0.86 %ID/g at 90 min.
Significantly inhibited tumor uptake to 0.35 %ID/g at 1 h postadministration when excess unlabeled NOTA-PTP was co-administered.
-
Animal Model:C57BL/6 (18−20 g, subcutaneous xenograft via injection of 2.5×10^6 KPC cells)[1]
-
Dosage:7.4−9.6 MBq (imaging); 0.925−1.11 MBq (biodistribution)
-
Administration:i.v.; single dose
-
Result:Showed significant tracer accumulation in tumors, with uptake of 1.75 %ID/g at 30 min postinjection via PET imaging.
Confirmed peak tumor uptake of 2.69 %ID/g at 0.5 h, decreasing to 1.53 %ID/g at 1 h and 0.91 %ID/g at 1.5 h via biodistribution analysis.
Achieved tumor-to-normal organ ratios at 1.5 h including tumor/muscle (4.38), tumor/liver (1.30), tumor/blood (3.57), and tumor/heart (2.66).
-
Animal Model:BALB/c nude (female, 18−20 g, subcutaneous xenograft via injection of 5×10^6 MIN-6 cells)[1]
-
Dosage:7.4−9.6 MBq (imaging); 0.925−1.11 MBq (biodistribution)
-
Administration:i.v.; single dose
-
Result:Showed minimal tracer accumulation in tumors, with uptake of 0.44 %ID/g at 30 min postinjection via PET imaging.
Confirmed tumor uptake of 0.69 %ID/g at 0.5 h, decreasing to 0.37 %ID/g at 1 h and 0.32 %ID/g at 1.5 h via biodistribution analysis.
-
Animal Model:C57BL/6 (18−20 g, orthotopic model via injection of KPC cells into pancreatic parenchyma; peritoneal metastasis model)[1]
-
Dosage:7.4−9.6 MBq
-
Administration:i.v.; single dose
-
Result:Clearly visualized both orthotopic pancreatic tumors and small peritoneal metastases at 45 min postinjection, with low background signal in major healthy organs, providing higher contrast than 2-[18F]FDG.
-
Animal Model:BALB/c (18−20 g, subcutaneous xenograft via injection of 4T1 cells into right hind limb)[1]
-
Dosage:7.4−9.6 MBq
-
Administration:i.v.; single dose
-
Result:Demonstrated definite tracer uptake in 4T1 tumor sites at 30 min postinjection.
Chemical Information
-
CAS No. 1192023-11-2
-
Masse moléculaire 768.94
-
Formule C36H64N8O10
-
Sequence
Lys-Thr-Leu-Leu-Pro-Thr-Pro
-
Sequence Shortening
KTLLPTP
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Wang T, et al. Radiosynthesis and Preclinical Evaluation of [Ga]Ga-NOTA-PTP Profiling Plectin-1 Expression for Pancreatic Cancer Imaging. Journal of medicinal chemistry. 2026 Feb 12;69(3):2888-2899. [Content Brief]
[2]. Kelly KA, et al. Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma. PLoS medicine. 2008 Apr 15;5(4):e85. [Content Brief]
[3]. Zhou L, et al. Active-Targeted ICG for Surgical Navigation and Fluorescence-Guided Laparoscopic Photothermal Ablation in Pancreatic Ductal Adenocarcinoma. Analytical chemistry. 2025 Jan 14;97(1):473-481. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
PTP peptide Related Classifications
HY-P11850 Related Classifications
Powered by Bioz
- PTP peptide
- 1192023-11-2
- Radionuclide-Drug Conjugates (RDCs)
- Pan-02 pancreatic ductal adenocarcinoma cells
- human PDAC tissue sections
- mouse PDAC lesions
- plectin-1
- HPDE6-C7 pancreatic ductal cells
- normal pancreatic ductal cells
- PanIN lesions
- human PDAC cell lines
- pancreatic ductal adenocarcinoma cells
- mouse PDAC cells
- Inhibitor
- inhibitor
- inhibit